<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657719</url>
  </required_header>
  <id_info>
    <org_study_id>GC3114_P2</org_study_id>
    <nct_id>NCT03657719</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects</brief_title>
  <official_title>Open-labeled(Part 1), Single-group(Part 2), Randomized(Part 2), Double-blind(Part 2), Active-controlled(Part 2) Pharse II Clinical Trial to Evaluate Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elderly healthy subjects will be once administered GC3114A(High-dose Quadrivalent influenza
      vaccine) or GCFLU Quadrivalent Pre-filled syringe inj..
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elderly healthy subjects will be once administered GC3114A(High-dose Quadrivalent influenza
      vaccine) or GCFLU Quadrivalent Pre-filled syringe inj..

      Safety and immunological efficacy will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">December 13, 2018</completion_date>
  <primary_completion_date type="Actual">December 13, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1 : Single group, Part2 : Parallel group</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Part 1 : Open label, Part 2 : Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>for 7 days from Day0/during study period</time_frame>
    <description>Solicited/Unsolicited Adverse Event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving pre-defined Seroconversion Before and following vaccination</measure>
    <time_frame>Day 0 and Day 28</time_frame>
    <description>Seroconversion rate (SCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving pre-defined Seroprotection Before and following vaccination</measure>
    <time_frame>Day 0 and Day 28</time_frame>
    <description>Seroprotection rate (SPR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Antibodies to the Investigational Product Before and Following vaccination</measure>
    <time_frame>Day 0 and Day 28</time_frame>
    <description>Geometric Mean Titer(GMT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio of Antibodies to the Investigational Product Before and Following vaccination</measure>
    <time_frame>Day 0 and Day 28</time_frame>
    <description>Geometric Mean Ratio(GMR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>GC3114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-filled syringe inj., 0.5ml, Once, IM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: GCFLU Quadrivalent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-filled syringe inj., 0.5ml, Once, IM</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC3114</intervention_name>
    <description>High-dose Quadrivalent influenza vaccine</description>
    <arm_group_label>GC3114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GCFLU Quadrivalent</intervention_name>
    <description>Quadrivalent influenza vaccine</description>
    <arm_group_label>Active Comparator: GCFLU Quadrivalent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults aged over 65 years old

          -  Informed consent form has been signed and dated

        Exclusion Criteria:

          -  Known systemic hypersensitive to eggs, chicken proteins, or any of the vaccine
             components

          -  Personal history of Guillain-Barre syndrome(GBS)

          -  Subjects with severe chronic disease who are considered by investigator to be
             ineligible for the study

          -  Subjects who received a vaccination within 28 days before enrollment or who are
             scheduled for another vaccination during the study

          -  Immunocompromised subjects with immunodeficiency disease or subjects receiving
             immunosuppressive or immunomodulating therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Woo Joo KIm, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>January 3, 2019</last_update_submitted>
  <last_update_submitted_qc>January 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

